FOXBIO
FoxBio is a developer of a small molecules techniques intended to reduce senescent cells in human bodies. The company's techniques targets the pro-survival pathways of senescent cells to remove them from the body, enabling patients to have multiple health benefits and delay the onset of age related diseases.
FOXBIO
Industry:
Biopharma Biotechnology Life Science
Founded:
2018-07-12
Address:
Lafayette, Louisiana, United States
Country:
United States
Status:
Closed
Total Funding:
10 M USD
Current Employees Featured
Kelsey Moody Founder & CEO @ FoxBio
Founder & CEO
Founder
Investors List
KIZOO Technology Capital
KIZOO Technology Capital investment in Venture Round - FoxBio
Juvenescence
Juvenescence investment in Venture Round - FoxBio
More informations about "FoxBio"
FoxBio - Crunchbase Company Profile & Funding
FoxBio is a developer of a small molecules techniques intended to reduce senescent cells in human bodies. The company's techniques targets the pro-survival pathways of senescent …See details»
FoxBio - Longevity List
FoxBio . Senolytic drug joint venture between Juvenescence and Ichor Therapeutics (Antoxerene) Website; Profile ... Ichor Therapeutics, Inc. is a premier, vertically integrated contract research …See details»
FoxBio Company Profile 2024: Valuation, Funding
FoxBio General Information Description. Developer of a small molecule technique therapy designed to reduce senescent cells in human bodies. The company's therapy targets the pro-survival pathways of senescent cells to remove them …See details»
FoxBio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore FoxBio, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news, and 1 literature.See details»
FoxBio - VentureRadar
FoxBio, Inc. is a joint venture between Antoxerene, Inc. and Juvenescence Limited. FoxBio will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence …See details»
FoxBio - liveforever.club
Jul 12, 2018 FoxBio, Inc. is a joint partnership between Juvenescence and Antoxerene, a portfolio company of Ichor Therapeutics. The company is focused on developing small …See details»
FoxBio - Products, Competitors, Financials, Employees, …
FoxBio, created by Antoxerene and Juvenescence, will develop Antoxerene's collection of small molecules that target senescent cells - cells that cause diseases, such as cancer, as people …See details»
FoxBio - Crunchbase
FoxBio is a Company that will develop Antoxerene’s collection of small molecules that target senescent cells. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
FoxBio Inc - Company Profile and News - Bloomberg Markets
Company profile page for FoxBio Inc including stock price, company news, executives, board members, and contact informationSee details»
FoxBio - Funding, Financials, Valuation & Investors - Crunchbase
FoxBio is a Company that will develop Antoxerene’s collection of small molecules that target senescent cells. Search Crunchbase. Start Free Trial . Chrome Extension. ... How much …See details»
Antoxerene Closes $10 Million Deal with Juvenescence to Develop …
The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence will support the venture with $10 million in equity …See details»
Research programme: small molecule therapeutics - FoxBio
Aug 28, 2022 FoxBio, a joint venture between Antoxerene and Juvenescence, is developing senolytic small molecules, originally developed by Antoxerene, for the treatment of ... If your …See details»
Antoxerene Closes $10 Million Deal with Juvenescence to
Jul 12, 2018 The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence will support the venture with $10 million …See details»
FoxBio Stock Price, Funding, Valuation, Revenue & Financial …
See FoxBio funding rounds, investors, investments, exits and more. Evaluate their financials based on FoxBio's post-money valuation and revenue. FoxBio Stock Price, Funding, …See details»
Antoxerene Closes $10 Million Deal with Juvenescence to Develop …
Jul 12, 2018 The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence will support the venture with $10 million …See details»
FoxBio - Updates, News, Events, Signals & Triggers - Crunchbase
FoxBio is a Company that will develop Antoxerene’s collection of small molecules that target senescent cells.See details»
FoxBio: $10m JV launched to target age-related disease
Jul 17, 2018 Antoxerene and investor firm Juvenescence have collaborated to form FoxBio Inc., an offshoot focused on small molecule drug discovery for the pathways of ageing. Antoxerene, …See details»
OBIO®
OBIO® supports early-stage and venture-backed life sciences and health tech companies enabling them to raise capital, hire and train industry-ready talent, facilitate the …See details»
Supercharging AAV Gene Therapy Development | Form Bio
Learn how Form Bio's computational platform enables data management, workflows, visualization and AI for cell and gene therapySee details»
Donald Trump gets Fox Nation Patriot of the Year award - USA …
1 day ago He also noted his close relations with some in the organization, saying: "You have incredible people at Fox." The appearance comes as Trump assembles his incoming …See details»